0001415889-19-000248.txt : 20190305 0001415889-19-000248.hdr.sgml : 20190305 20190305160520 ACCESSION NUMBER: 0001415889-19-000248 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190301 FILED AS OF DATE: 20190305 DATE AS OF CHANGE: 20190305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AHMED NADIM CENTRAL INDEX KEY: 0001731193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 19658273 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 4 1 form4-03052019_040307.xml X0306 4 2019-03-01 0000816284 CELGENE CORP /DE/ CELG 0001731193 AHMED NADIM C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 false true false false PRES., HEMATOLOGY AND ONCOLOGY Restricted Stock Unit 2019-03-01 4 A 0 27749 0 A Common Stock 27749 27749 D Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. President, Inflammation and Immunology /s/ Mark J. Alles, Attorney-in-Fact 2019-03-05